Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012
- PMID: 26463436
- PMCID: PMC4695455
- DOI: 10.3802/jgo.2016.27.e5
Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012
Abstract
Objective: To investigate trends in the incidence of epithelial ovarian cancer (EOC), according to histologic subtypes, in Korean women between 1999 and 2012.
Methods: Data from the Korea Central Cancer Registry recorded between 1999 and 2012 were evaluated. The incidences of EOC histologic subtypes were counted. Age-standardized incidence rates (ASRs) and annual percentage changes (APCs) in incidence rates were calculated. Patient data were divided into three groups based on age (<40, 40 to 59, and >59 years), and age-specific incidence rates were compared.
Results: Overall, the incidence of EOC has increased. Annual EOC cases increased from 922 in 1999 to 1,775 in 2012. In 1999, the ASR was 3.52 per 100,000 and increased to 4.79 per 100,000 in 2012 (APC, 2.53%; p<0.001). The ASRs in 2012 and APCs between 1999 and 2012 for the four major histologic subtypes were as follows (in order of incidence): serous carcinoma (ASR, 2.32 per 100,000; APC, 4.34%; p<0.001), mucinous carcinoma (ASR, 0.73 per 100,000; APC, -1.05%; p=0.131), endometrioid carcinoma (ASR, 0.51 per 100,000; APC, 1.48%; p=0.032), and clear cell carcinoma (ASR, 0.50 per 100,000; APC, 8.13%; p<0.001). In the sub-analyses based on age, clear cell carcinoma was confirmed as the histologic subtype whose incidence had increased the most since 1999.
Conclusion: The incidence of EOC is increasing in Korea. Among the histologic subtypes, the incidence of clear cell carcinoma has increased markedly across all age groups since 1999.
Keywords: Histologic Subtype; Incidence; Ovarian Neoplasms; Time Trends.
Conflict of interest statement
Figures
Similar articles
-
Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.J Clin Oncol. 2016 Aug 20;34(24):2888-98. doi: 10.1200/JCO.2016.66.8178. Epub 2016 Jun 20. J Clin Oncol. 2016. PMID: 27325851 Free PMC article.
-
Global distribution pattern of histological subtypes of epithelial ovarian cancer: a database analysis and systematic review.Gynecol Oncol. 2014 May;133(2):147-54. doi: 10.1016/j.ygyno.2014.02.016. Epub 2014 Feb 17. Gynecol Oncol. 2014. PMID: 24556058 Review.
-
TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.Exp Mol Pathol. 2013 Oct;95(2):235-41. doi: 10.1016/j.yexmp.2013.08.004. Epub 2013 Aug 18. Exp Mol Pathol. 2013. PMID: 23965232
-
Birth weight and the risk of histological subtypes of ovarian and endometrial cancers: Results from the Copenhagen School Health Records Register.Gynecol Oncol. 2018 Mar;148(3):547-552. doi: 10.1016/j.ygyno.2017.12.031. Epub 2018 Jan 11. Gynecol Oncol. 2018. PMID: 29331371 Free PMC article.
-
Prevalence of endometriosis in ovarian cancer.Gynecol Obstet Invest. 2000;50 Suppl 1:11-7. doi: 10.1159/000052873. Gynecol Obstet Invest. 2000. PMID: 11093056 Review.
Cited by
-
The surgical, histopathological characteristics, and survival outcome of ovarian clear cell carcinoma: a retrospective case series sharing the experience of a tertiary cancer centre.Transl Cancer Res. 2024 Sep 30;13(9):5037-5049. doi: 10.21037/tcr-24-83. Epub 2024 Sep 11. Transl Cancer Res. 2024. PMID: 39430857 Free PMC article.
-
Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis.J Gynecol Oncol. 2018 Mar;29(2):e18. doi: 10.3802/jgo.2018.29.e18. Epub 2017 Dec 11. J Gynecol Oncol. 2018. PMID: 29400011 Free PMC article.
-
Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience.J Gynecol Oncol. 2024 Sep;35(5):e69. doi: 10.3802/jgo.2024.35.e69. Epub 2024 Mar 29. J Gynecol Oncol. 2024. PMID: 38606821 Free PMC article.
-
Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer.Yonsei Med J. 2020 Nov;61(11):935-941. doi: 10.3349/ymj.2020.61.11.935. Yonsei Med J. 2020. PMID: 33107236 Free PMC article.
-
Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy.J Korean Med Sci. 2017 Dec;32(12):2021-2028. doi: 10.3346/jkms.2017.32.12.2021. J Korean Med Sci. 2017. PMID: 29115086 Free PMC article.
References
-
- Agarwal R, Kaye SB. Prognostic factors in ovarian cancer: how close are we to a complete picture? Ann Oncol. 2005;16:4–6. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous